Good question. I am no expert, but yes, approval for animal use can be quicker and much cheaper and is often done as a secondary opportunity to human trials. This article is a few years old but explains the difference in simple terms
https://www.linkedin.com/pulse/how-human-veterinary-drugs-go-from-concept-commercial-barksdale
And just to remind us all of the fda fast track approval process we are looking at for btx1801
https://www.fda.gov/drugs/development-approval-process-drugs
Ann: BTX 1702 Rosacea Study Approval, page-53
-
- There are more pages in this discussion • 49 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
36.0¢ |
Change
0.015(4.35%) |
Mkt cap ! $651.6M | |||
| Open | High | Low | Value | Volume |
| 34.5¢ | 36.5¢ | 34.5¢ | $1.231M | 3.443M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 156338 | 35.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 36.5¢ | 444065 | 17 |
View Market Depth
| Last trade - 16.10pm 22/08/2024 (20 minute delay) ? |
| BOT (ASX) Chart |